Page 4 - Expansion Study News Today

MONTRÉAL, July 12, 2022 (GLOBE NEWSWIRE) -- Osisko Gold Royalties Ltd (the “Corporation” or “Osisko”) (OR: TSX & NYSE) is pleased to provide an...

TORONTO, June 28, 2022 (GLOBE NEWSWIRE) -- Alamos Gold Inc. (TSX:AGI; NYSE:AGI) (“Alamos” or the “Company”) today reported results of the Phase 3+...

Resumption of Normal Operations at San BartoloméIntersection of Porphyry Intrusion at San Pablo Initial Results from Dry-Stack Tailings Drill ProgramToronto,...

New data from Expansion Study 102 in high-risk, LA-HNSCC patients highlights potential clinical benefit of NBTXR3 showing a median Overall Survival reaching 23 months in evaluable patients; Data

For personal use only ASX ANNOUNCEMENT 15 March 2022 | ASX:FHE ... | March 14, 2022

Measured and Indicated Mineral Resources of 27.5 Million Ounces of Silver and 11.9 Thousand Tonnes of Tin;Inferred Mineral Resources of 3.8 Million Ounces of Silver and 1.3 Thousand Tonnes of TinToronto

Press release content from Business Wire. The AP news staff was not involved in its creation.

Evaluation of NBTXR3 for global registration in priority head and neck cancer pathway proceeds with the first European patient randomized in global phase III NANORAY-312 study; US and Asia site

Technical studies to extend the mine life at San Bartolome are advancing with NI 43-101 Mineral Resource Statement for Silver and Tin expected January Toronto, Ontario--(Newsfile Corp. - December 14,

Nanobiotix Announces Key Development Milestones for 2021 After Successful Nasdaq Initial Public Offering Nanobiotix will use a portion of the proceeds from the its IPO to launch its global phase III registration study in head and neck cancer in the United States in 2021 Following previously reported preliminary data regarding the ability of NBTXR3 to help transform anti-PD-1 non-responders into responders, the Company will provide the next update on its immuno-oncology phase I basket study eval...